Celcuity Inc. announced that REVTORPYK (gedatolisib), an FDA-approved breast cancer therapy, is commercially available in the US. The launch follows recent regulatory approvals and positions the company in the advanced breast cancer market.
Celcuity Inc. announced that REVTORPYK (gedatolisib), an FDA-approved breast cancer therapy, is commercially available in the US. The launch follows recent regulatory approvals and positions the company in the advanced breast cancer market.